Mercy Ibarra joined the MJ team as an account manager in our Benefits Consulting department and quickly moved up to the role of client executive. In this position, Mercy and her team work to provide comprehensive benefit strategies, health and wellness programs, and compliance services to their clients.
As a seasoned professional, Mercy develops the most cost-effective and strategic benefit options and programs for our clients. She is their primary point of contact and acts as an advocate on their behalf. She enjoys creating effective communication materials and helping our clients navigate the ever-changing world of health care.
Related Blogs
Health Care Industry Trends to Watch in 2026
Health care organizations enter 2026 facing numerous operational, financial and liability pressures, including labor shortages, inflation, supply chain volatility and the impact of U.S. ...
Read More
2025 Ended with Softest Market Conditions Since 2017 for all Account Sizes & Majority of Lines of Business, The Council’s P/C Market Survey Shows
The market appeared to move further into the soft part of the insurance market cycle in Q4 2025. Premiums across all account sizes rose ...
Read More
Miles for Miles Helps People With Intellectual and Developmental Disabilities Thrive
Miles Peck loves school as much for the chance to spend time with his friends as for the classroom experience. He is bracing his ...
Read More
EBSA Updates National Employee Benefit Plan Enforcement Projects for 2026
The Employee Benefits Security Administration (EBSA) announced updates to its national enforcement projects for fiscal year 2026. According to EBSA, these projects highlight areas ...
Read More
The Hard Market Is Shifting—Here’s What That Means for YOU
For years, organizations have been told the same thing at renewal: higher costs, fewer options, and little room to negotiate. Now, that message is ...
Read More
Employer Response to Pharma Shifts
Volatility in the pharmaceutical industry, including the expanding specialty drug pipeline, increased utilization of GLP-1 medications, and persistent supply chain disruptions, are contributing to rising costs ...
Read More